Intravenous Iron Dextran as a Component of Anemia Management in Chronic Kidney Disease: A Report of Safety and Efficacy

Table 1

Patient demographics and baseline characteristics.

Baseline results	IV iron	Oral iron	𝑃 value
	(𝑛=50)	(𝑛=100)
Demographics
Age, years	69.1 ± 12.9	65 ± 13.5	0.061^†
Race, 𝑛 (White/Black/Asian/Hispanic)	10/40/0/0	14/83/1/2	0.654^#
Gender, 𝑛 (male/female)	23/27	45/55	1.000^χ
Former medical history, 𝑛
Congestive heart failure	18 (36%)	13 (13%)	0.001^χ
Coronary artery disease	12 (24%)	16 (16%)	0.236^χ
Hypertension	49 (98%)	97 (97%)	1.000^#
Diabetes	25 (50%)	54 (54%)	0.643^χ
Laboratory
Hb (g/dL)	9.4 ± 0.8	10.9 ± 1.2	<0.001^†
TSAT%	12.9 ± 4.0	23.2 ± 5.8	<0.001^†
Ferritin (ng/mL)	134.7 ± 151.5	216.7 ± 146.0	<0.005^†

^†2-sample  𝑡-test, ^χChi-square, ^#Fisher exact.
Demographics are reported as frequencies except for age which is reported as a mean. Variables under past medical history are reported as frequencies with percentages in parenthesis. Laboratory parameters are reported as means + SD. 𝑃 value > 0.05 was considered nonsignificant (n.s.).